mspipeline

I added ATX-MS1467 from Apitope Technology to the phase 1 list based on this.

I moved HP184 (Sanofi-Aventis), from pre-clinical to phase 2. It is now called nerispirdine. Based on this, HP184 is a K+ / Na+ channel blocker. Channel blockers have shown some promise in offering neuroprotection, so let’s hope this one is successful.

I added a trial of Sunphenon EGCg (Epigallocatechin-Gallate) to the phase 2 list based on this.

I moved Peptimmune’s PI-2301 from pre-clinical to phase 1 based on this.

Based on this information from the MS Society of Canada, I added minocycline to phase 3. Woohoo! I’m keeping it in phase 2 as well because there are two phase 2 trials with minocycline ongoing.

Based on this report that the new Rebif formulation has been approved by the EU regulatory authority, I ‘m taking the trial out of phase 3 and updating the approved list to reflect that rebif is the “new version”.